|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
2
|
Cartier N, Hacein-Bey-Abina S, Bartholomae
CC, et al: Hematopoietic stem cell gene therapy with a lentiviral
vector in X-linked adrenoleukodystrophy. Science. 326:818–823.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shiseki M, Nagashima M, Pedeux RM, et al:
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.
Cancer Res. 63:2373–2378. 2003.PubMed/NCBI
|
|
4
|
Zhang X, Xu LS, Wang ZQ, et al: ING4
induces G2/M cell cycle arrest and enhances the chemosensitivity to
DNA-damage agents in HepG2 cells. FEBS Lett. 570:7–12. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie Y, Zhang H, Sheng W, Xiang J, Ye Z and
Yang J: Adenovirus-mediated ING4 expression suppresses lung
carcinoma cell growth via induction of cell cycle alteration and
apoptosis and inhibition of tumor invasion and angiogenesis. Cancer
Lett. 271:105–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cai L, Li X, Zheng S, et al: Inhibitor of
growth 4 is involved in melanomagenesis and induces growth
suppression and apoptosis in melanoma cell line M14. Melanoma Res.
19:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xie YF, Sheng W, Xiang J, Zhang H, Ye Z
and Yang J: Adenovirus-mediated ING4 expression suppresses
pancreatic carcinoma cell growth via induction of cell-cycle
alteration, apoptosis, and inhibition of tumor angiogenesis. Cancer
Biother Radiopharm. 24:261–269. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Colla S, Tagliaferri S, Morandi F, et al:
The new tumor-suppressor gene inhibitor of growth family member 4
(ING4) regulates the production of proangiogenic molecules by
myeloma cells and suppresses hypoxia-inducible factor-1 alpha
(HIF-1alpha) activity: involvement in myeloma-induced angiogenesis.
Blood. 110:4464–4475. 2007. View Article : Google Scholar
|
|
9
|
Li Z, Xie Y, Sheng W, Miao J, Xiang J and
Yang J: Tumor-suppressive effect of adenovirus-mediated inhibitor
of growth 4 gene transfer in breast carcinoma cells in vitro and in
vivo. Cancer Biother Radiopharm. 25:427–437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang H, Lin JJ, Su ZZ, Goldstein NI and
Fisher PB: Subtraction hybridization identifies a novel melanoma
differentiation associated gene, mda-7, modulated during human
melanoma differentiation, growth and progression. Oncogene.
11:2477–2486. 1995.
|
|
11
|
Sauane M, Gopalkrishnan RV, Sarkar D, et
al: MDA-7/IL-24: novel cancer growth suppressing and apoptosis
inducing cytokine. Cytokine Growth Factor Rev. 14:35–51. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fisher PB: Is mda-7/IL-24 a ‘magic bullet’
for cancer? Cancer Res. 65:10128–10138. 2005.
|
|
13
|
Saeki T, Mhashilkar A, Swanson X, et al:
Inhibition of human lung cancer growth following
adenovirus-mediated mda-7 gene expression in vivo. Oncogene.
21:4558–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ramesh R, Mhashilkar AM, Tanaka F, et al:
Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a
novel ligand that regulates angiogenesis via the IL-22 receptor.
Cancer Res. 63:5105–5113. 2003.PubMed/NCBI
|
|
15
|
Nishikawa T, Ramesh R, Munshi A, Chada S
and Meyn RE: Adenovirus-mediated mda-7 (IL-24) gene therapy
suppresses angiogenesis and sensitizes NSCLC xenograft tumors to
radiation. Mol Ther. 9:818–828. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inoue S, Branch CD, Gallick GE, Chada S
and Ramesh R: Inhibition of Src kinase activity by Ad-mda7
suppresses vascular endothelial growth factor expression in
prostate carcinoma cells. Mol Ther. 12:707–715. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ramesh R, Ito I, Gopalan B, Saito Y,
Mhashilkar AM and Chada S: Ectopic production of MDA-7/IL-24
inhibits invasion and migration of human lung cancer cells. Mol
Ther. 9:510–518. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pei Z, Chu L, Zou W, et al: An oncolytic
adenoviral vector of Smac increases antitumor activity of TRAIL
against HCC in human cells and in mice. Hepatology. 39:1371–1381.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen Y, Muramatsu SI, Ikeguchi K, et al:
Triple transduction with adeno-associated virus vectors expressing
tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP
cyclohydrolase I for gene therapy of Parkinson’s disease. Hum Gene
Ther. 11:1509–1519. 2000.
|
|
20
|
Ngoi SM, Chien AC and Lee CG: Exploiting
internal ribosome entry sites in gene therapy vector design. Curr
Gene Ther. 4:15–31. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sheng WH, Xie YF, Miao JC, et al: The
anti-tumor effect by adenovirus-mediated ING4 and IL-24
co-expression on hepatocellular carcinoma in vitro. Chin J
Microbiol Immunol. 30:695–703. 2010.
|
|
22
|
Weidner N: Current pathologic methods for
measuring intratumoral microvessel density within breast carcinoma
and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995.
View Article : Google Scholar
|
|
23
|
Wang W, Qin SK, Chen BA and Chen HY:
Experimental study on antitumor effect of arsenic trioxide in
combination with cisplatin or doxorubicin on hepatocellular
carcinoma. World J Gastroenterol. 7:702–705. 2001.PubMed/NCBI
|
|
24
|
Garkavtsev I, Kozin SV, Chernova O, et al:
The candidate tumour suppressor protein ING4 regulates brain tumour
growth and angiogenesis. Nature. 428:328–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wilson DR: Viral-mediated gene transfer
for cancer treatment. Curr Pharm Biotechnol. 3:151–164. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Meijerink JP, Smetsers TF, Slöetjes AW,
Linders EH and Mensink EJ: Bax mutations in cell lines derived from
hematological malignances. Leukemia. 9:1828–1832. 1995.PubMed/NCBI
|
|
27
|
Danial NN and Korsmeyer SJ: Cell death:
critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Adida C, Crotty PL, McGrath J, Berrebi D,
Diebold J and Altieri DC: Developmentally regulated expression of
the novel cancer anti-apoptosis gene survivin in human and mouse
differentiation. Am J Pathol. 152:43–49. 1998.PubMed/NCBI
|
|
29
|
AItieri DC: The molecular basis and
potential role of survivin in cancer diagnosis and therapy. Trends
Mol Med. 7:542–547. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harper JW, Adami GR, Wei N, Keyomarsi K
and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Niculescu AB III, Chen X, Smeets M, Hengst
L, Prives C and Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S
and the G2/M cell cycle transitions: pRb is a critical determinant
in blocking DNA replication and in preventing endoreduplication.
Mol Cell Biol. 18:629–643. 1998.PubMed/NCBI
|
|
32
|
Smits VA, Klompmaker R, Vallenius T,
Rijksen G, Mäkela TP and Medema RH: p21 inhibits Thr161
phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J
Biol Chem. 275:30638–30643. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Toyoshima H and Hunter T: p27, a novel
inhibitor of G1 cyclin-Cdk protein kinase activity, is related to
p21. Cell. 78:67–74. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Petrova TV, Makinen T and Alitalo K:
Signaling via vascular endothelial growth factor receptors. Exp
Cell Res. 253:117–130. 1999. View Article : Google Scholar : PubMed/NCBI
|
